Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1611 drug-drug interaction study with itraconazole or fluvoxamine in healthy subjects
NL-OMON51334Completed
- Sponsor
- Menarini Group
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of izorlisib (2 arms), sponsored by Menarini Group. Primary endpoint: Effect of CYP3A4/P-gp or CYP1A2/3A4 inhibition on MEN1611 pharmacokinetics. Started Jun 2022; status: completed.
02
Drugs
izorlisib
Beyond the preview
Go deeper on NL-OMON51334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51334.